These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32358817)

  • 1. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome.
    Odièvre MH; de Marcellus C; Ducou Le Pointe H; Allali S; Romain AS; Youn J; Taytard J; Nathan N; Corvol H
    Am J Hematol; 2020 Aug; 95(8):E192-E194. PubMed ID: 32358817
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab.
    De Luna G; Habibi A; Deux JF; Colard M; Pham Hung d'Alexandry d'Orengiani AL; Schlemmer F; Joher N; Kassasseya C; Pawlotsky JM; Ourghanlian C; Michel M; Mekontso-Dessap A; Bartolucci P
    Am J Hematol; 2020 Jul; 95(7):876-878. PubMed ID: 32282956
    [No Abstract]   [Full Text] [Related]  

  • 3. Tocilizumab for COVID-19: a real 'miracle drug'?
    Nasim S; Hashmi SH; Azim D; Kumar S; Nasim J
    Infect Dis (Lond); 2020 Sep; 52(9):681-682. PubMed ID: 32644027
    [No Abstract]   [Full Text] [Related]  

  • 4. Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations.
    Taher AT; Bou-Fakhredin R; Kreidieh F; Motta I; De Franceschi L; Cappellini MD
    Am J Hematol; 2020 Aug; 95(8):E208-E210. PubMed ID: 32394480
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient.
    Beerkens F; John M; Puliafito B; Corbett V; Edwards C; Tremblay D
    Am J Hematol; 2020 Jul; 95(7):E154-E156. PubMed ID: 32243621
    [No Abstract]   [Full Text] [Related]  

  • 6. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.
    Gade AR; Alavala H; Allam SR
    Kidney Int; 2020 Oct; 98(4):1054. PubMed ID: 32650019
    [No Abstract]   [Full Text] [Related]  

  • 7. Tocilizumab in COVID-19: Beware the risk of intestinal perforation.
    Vikse J; Henry BM
    Int J Antimicrob Agents; 2020 Jul; 56(1):106009. PubMed ID: 32389721
    [No Abstract]   [Full Text] [Related]  

  • 8. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
    Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N
    Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518
    [No Abstract]   [Full Text] [Related]  

  • 9. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
    Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
    Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
    [No Abstract]   [Full Text] [Related]  

  • 10. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.
    Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A
    Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612
    [No Abstract]   [Full Text] [Related]  

  • 11. Early tocilizumab treatment could improve survival among COVID-19 patients.
    Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L
    Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.
    Mihai C; Dobrota R; Schröder M; Garaiman A; Jordan S; Becker MO; Maurer B; Distler O
    Ann Rheum Dis; 2020 May; 79(5):668-669. PubMed ID: 32241792
    [No Abstract]   [Full Text] [Related]  

  • 13. First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19.
    Mastroianni F
    Chest; 2020 Nov; 158(5):2233. PubMed ID: 33160536
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytokine release syndrome in severe COVID-19.
    Moore JB; June CH
    Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
    [No Abstract]   [Full Text] [Related]  

  • 15. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws.
    Bennardo F; Buffone C; Giudice A
    Oral Oncol; 2020 Jul; 106():104659. PubMed ID: 32209313
    [No Abstract]   [Full Text] [Related]  

  • 16. Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19.
    Kishfy L; Casasola M; Banankhah P; Parvez A; Jan YJ; Shenoy AM; Thomson C; AbdelRazek MA
    J Neurol Sci; 2020 Jul; 414():116943. PubMed ID: 32474362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [First case of COVID-19 treated with tocilizumab in Iceland].
    Bjornsson AH; Olafsdottir T; Thormar KM; Kristjansson M; Thorisdottir AS; Ludviksson BR; Guðmundsson S; Gottfredsson M
    Laeknabladid; 2020 Mai; 106(5):247-250. PubMed ID: 32367812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The complement inhibitors in COVID-19: future expectations.
    Korotchaeva Y; Kozlovskaya N; Bobrova L; Kamyshova E; Demyanova K; Moiseev S
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6480-6481. PubMed ID: 32633332
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytokine Storm Drugs Move from CAR T to COVID-19.
    Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of tocilizumab effect on mortality in COVID19 patients.
    Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
    Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.